AngioScore, founded in 2003, operates in the Biotechnology and Health Care industries, with its headquarters in the United States. The company's flagship product, the AngioSculpt Scoring Balloon Catheter, has revolutionized the treatment of peripheral arterial disease (PAD) and coronary artery disease (CAD). The innovative nitinol scoring element enables precise and predictable dilatation across a wide range of lesion types, providing versatility and effectiveness. In April 2011, AngioScore secured a significant $12.00M Venture Round investment from Saints Capital, further validating the potential of its groundbreaking technology. This investment solidifies the company's position in the market and signifies investor confidence in its innovative approach to addressing critical medical conditions. With its pioneering technology and the backing of prominent investors, AngioScore is well-positioned for continued growth and impact in the healthcare landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $12.00M | 1 |
|
20 Apr 2011 |
| Series E | $30.00M | 6 |
|
09 Oct 2007 |
| Series D | $30.00M | 3 |
|
11 Apr 2006 |
| Series B | $15.00M | - | 23 Aug 2004 |
No recent news or press coverage available for AngioScore.
We care about your data, and we'd love to use cookies make your experience better.
